Who owns PPH - MARKET VECTORS ETF TR - PHARMACEUTICAL based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

MARKET VECTORS ETF TR - PHARMACEUTICAL (PPH) Institutional Ownership

Q: What is CUSIP 57060U217?

CUSIP 57060U217 is the security identifier used in SEC filing datasets for PPH - MARKET VECTORS ETF TR - PHARMACEUTICAL.

CUSIP: 57060U217

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2017

Type / Class: Equity / PHARMACEUTICAL
Symbol: PPH

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 57060U217?
CUSIP 57060U217 identifies PPH - MARKET VECTORS ETF TR - PHARMACEUTICAL in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 57060U217:

Q1 2017 (0 holders) Q4 2016 (1 holder) Q3 2016 (2 holders) Q2 2016 (3 holders) Q1 2016 (54 holders) Q4 2015 (57 holders) Q3 2015 (58 holders) Q2 2015 (60 holders) Q1 2015 (50 holders) Q4 2014 (56 holders)

Institutional Holders of MARKET VECTORS ETF TR - PHARMACEUTICAL (PPH) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2017 Q1	0	$0	-$210,000				0
2016 Q4	4,000	$210,000	-$477,000			$52.50	1
2016 Q3	11,685	$706,000	+$76,000			$59.66	2
2016 Q2	10,850	$635,000	-$153,179,325	$0		$58.50	3
2016 Q1	2,677,504	$153,942,750	-$48,501,424	$448,000	$0	$57.48	54
2015 Q4	3,444,069	$224,933,532	+$3,442,589		$261,000	$65.31	57
2015 Q3	2,489,905	$156,802,298	-$18,137,783		$737,000	$62.97	58
2015 Q2	2,747,166	$194,312,958	+$90,894,968			$70.75	60
2015 Q1	1,416,712	$99,533,024	-$15,582,262			$70.24	50
2014 Q4	1,668,971	$107,281,784	-$26,171,017			$64.27	56
2014 Q3	1,899,348	$120,586,114	+$40,649,356			$63.57	47
2014 Q2	1,260,319	$78,200,904	+$27,299,176			$62.04	51
2014 Q1	823,001	$48,001,022	+$4,645,659			$58.37	51